Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis
Shots:
- Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer
- Accordingly- Novartis will acquire equity stake in Laenka adding upfront fees and milestones including royalties
- A second agreement b/w them in addition CFG920(CYP17 inhibitor) licensing- an oral androgen inhibitor- for prostate cancer
Ref: US FDA | Image: Crunchbase
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com